Eli Lilly and Company (LLY) vs Merck & Co., Inc. (MRK)

See how Eli Lilly and Company and Merck & Co., Inc. differ across market data and performance, so you can decide which asset best fits your strategy.

$1,280.79
NYSE
Eli Lilly & Co. is a pharmaceutical company focused on neuroscience, cardiometabolic disease, oncology, and immunology. Its leading products include Verzenio and Jaypirca in cancer treatment; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin in cardiometabolic care; and Taltz and Olumiant in immunology.
View Full Page
$152.23
NYSE
Merck & Co., Inc. develops pharmaceutical products across multiple therapeutic areas, including cardiometabolic disorders, oncology, and infectious diseases. In cancer treatment, its immuno-oncology portfolio, led by Keytruda, represents a significant driver of total revenue. The company also maintains a strong vaccines business focused on preventing pediatric illnesses, alongside Gardasil for human papillomavirus. In addition, Merck markets animal health products. Geographically, 47% of the company’s sales come from its U.S. human health segment, which includes pharmaceuticals and vaccines.
View Full Page

Key Metrics Comparison

Eli Lilly and CompanyLLY
Market Cap
$1.142T
Price
$1,280.79
24h Change
+4.49%
24h Volume
$3.75M
Employees
50,000
Shares Outstanding
944,818,881
Merck & Co., Inc.MRK
Market Cap
$375.578B
Price
$152.23
24h Change
+12.62%
24h Volume
$29.34M
Employees
73,000
Shares Outstanding
2,469,879,206

Category Performance

Visual comparison across key categories. Ring fill represents relative strength or share between the two assets.

Market Share

Share of combined market cap

Market Share
LLY
75.2%
MRK
24.8%

Volume Share

Share of combined 24h volume

Volume Share
LLY
11.3%
MRK
88.7%

24h Performance

Price change over last 24 hours

24h Performance
LLY
4.49%
MRK
12.62%
Price Comparison
Eli Lilly and Company
Merck & Co., Inc.